Protana, located in Odense, Denmark is a leading protein sequence analysis, bioinformatics and drug target characterization, services company. These technologies will accelerate the identification of new pharmaceutical and diagnostic tests to enhance the health and well-being of people around the world.
Proteomics is the next wave of molecular medicine after genomics.
This is MDS's second initiative in the emerging proteomics area. In February of 1999, MDS formed a research collaboration with the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto to support research in the area of proteomics focused on protein-protein interactions, an area of increasing interest to pharmaceutical companies for drug discovery and development. MDS Inc., is a broad-based, international health and life sciences company. Its core purpose is to make a distinctive contribution to the health and well-being of people. MDS employs more than 7,000 highly skilled people at its global operations in Canada and the United States, as well as in Europe and Asia.